Pediatric Atopic Dermatitis Linked to Shorter Stature in TriNetX Analysis
![<![CDATA[How Atopic Dermatitis May Affect Growth and Bone Health in Children]]>](/media/8e/8e39d565e74b4aa8.1280.webp)
Children with atopic dermatitis had a 15% higher relative risk of height below the fifth percentile than matched controls, according to a 2025 retrospective cohort analysis of the TriNetX database (relative risk, 1.15; 95% CI, 1.12–1.18). The figure anchors a growing clinical question: does chronic, uncontrolled pediatric AD shape growth and bone health, and can systemic treatment change that trajectory?
Lisa Swanson, MD, tackled that question in the Dermatology Times Expert Perspectives series Beyond the Skin: Sleep, Steroids, and Growth in Children With Atopic Dermatitis. Her discussion covers three linked threads — disease burden, sleep disruption, and emerging dupilumab data — and where the evidence actually stops.
What does the growth signal show?
The TriNetX cohort study is observational, and Swanson's framing is careful on that point: it suggests an association between pediatric AD and shorter stature, but it cannot establish causality. No single mechanism explains height or bone differences in these children, and available evidence doesn't offer one.
Growth concerns cluster in two groups: children with longstanding, poorly controlled disease, and children already tracking at lower percentiles on standardized growth charts. In those patients, clinicians have to parse whether a growth pattern reflects disease burden, treatment exposure — including corticosteroid exposure — normal developmental variation, or a mix of all three.
How does sleep fit in?
Sleep disruption is among the most consequential burdens of pediatric AD. Persistent nocturnal pruritus drives repeated nighttime awakenings, fragments restorative sleep, and drags fatigue and reduced quality of life across the whole family.
The physiological stake is concrete: growth hormone secretion is tied to sleep, and normal sleep patterns feed the processes of bone development and remodeling. That connection has pushed researchers to ask whether calming itch and restoring sleep could carry downstream effects on growth — which is exactly where the dupilumab data enter.
Is dupilumab a growth story yet?
Not quite. A 2026 post hoc analysis, discussed in the series, examined height outcomes and bone alkaline phosphatase (BALP) — a biomarker of bone formation — in children receiving dupilumab (Dupixent) for severe AD.
The investigators proposed that better itch and disease control could indirectly support growth-related outcomes through improved sleep. But sleep wasn't directly measured in the analysis, so the pathway remains a hypothesis, not a demonstrated mechanism.
Two caveats matter for interpretation. BALP reflects bone formation activity; it doesn't measure bone mineral density or prove long-term skeletal benefit. And shifts in height percentiles need reading against age, baseline growth patterns, treatment duration, and other influences. The findings raise clinically relevant questions about the broader effects of controlling severe AD — they don't establish that dupilumab builds bone density or stimulates growth.
What does this change for the clinic?
For now, it changes the conversation, not the prescription. Swanson's practical guidance centers on distinguishing established evidence from emerging associations from open questions — especially when parents ask whether inflammation, lost sleep, or medications will affect their child's eventual height.
The workflow she outlines is modest and actionable:
- Routinely assess growth patterns and height trajectories
- Ask about sleep quality, nighttime itching, and daily functioning
- Evaluate disease control alongside growth data, not separately
- Involve pediatricians or specialists for persistent growth abnormalities
One point deserves emphasis: the AD–growth association is not a prediction that every child with AD will have impaired development. It flags the value of individualized assessment in severe or inadequately controlled disease — the subset where growth monitoring and sleep questions earn their place in the visit.
As research clarifies how inflammation, sleep, treatment response, and skeletal development interact, growth and bone surveillance look set to become a standing component of comprehensive pediatric AD management.
Source: dermatologytimes.com
Olivia Hart
Show full bio
News editor covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.